To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 19, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

February 29, 2028

Conditions

Transthyretin Amyloid Polyneuropathy

Interventions

DRUG

Tafamidis Meglumine Soft Capsules

20 mg orally once daily for 72 weeks

Trial Locations (1)

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY